(R)-Ambrisentan-d3
CAS No. 1007358-76-0
(R)-Ambrisentan-d3 ( —— )
Catalog No. M23102 CAS No. 1007358-76-0
(R)-Ambrisentan-d3 is the deuterated version of (R)-Ambrisentan (A575873), which is the R-isomer impurity of Ambrisentan (A575860) that is a nonpeptide endothelin ETA receptor antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
10MG | 468 | In Stock |
|
25MG | 1020 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(R)-Ambrisentan-d3
-
NoteResearch use only, not for human use.
-
Brief Description(R)-Ambrisentan-d3 is the deuterated version of (R)-Ambrisentan (A575873), which is the R-isomer impurity of Ambrisentan (A575860) that is a nonpeptide endothelin ETA receptor antagonist.
-
Description(R)-Ambrisentan-d3 is the deuterated version of (R)-Ambrisentan (A575873), which is the R-isomer impurity of Ambrisentan (A575860) that is a nonpeptide endothelin ETA receptor antagonist, used as antihypertensive drug.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1007358-76-0
-
Formula Weight378.42
-
Molecular FormulaC22H22N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Riechers, H., et al.: J. Med. Chem., 39, 2123 (1996); Billman, G.E., et al.: Curr. Opin. Invest. Drugs, 3, 1483 (2002); Vatter, H., et al.: Clin. Neuropharmacol., 26, 73 (2003)
molnova catalog
related products
-
Tetrahydrozoline HCl
Tetrahydrozoline HCl is an imidazoline derivative with alpha receptor agonist activity.
-
Gracillin
Gracillin can induce cell cycle arrest, oxidative stress, and apoptosis in HL60 cells, and has the potential to be developed as an antitumor agent.
-
ISOTHIAZOLINE 1,1-DI...
ISOTHIAZOLINE 1,1-DIOXIDE is a reactant used in the synthesis of orally bioavailable hebatits B caspid inhibitors, and in the preparation of cryptochrome imhibitors as antidiabetic agents.